Gheuens Sarah's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Mar 3, 2026
- Accession no.
- 0001439222-26-000040
- Filed
- Mar 3, 2026
- Trade date
- Mar 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 6 derivative transactions. Open-market sales total $117.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gheuens SarahCIK 0001881190 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +4,000 | $0.00 | $0 | 68,795 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −1,187 | $28.96 | −$34,375.52 | 67,608 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +5,666 | $0.00 | $0 | 73,274 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −1,681 | $28.96 | −$48,681.76 | 71,593 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseAcquired | +4,000 | $0.00 | $0 | 75,593 | Direct | |
| Mar 2, 2026 | Common stock | SSaleDisposed | −1,187 | $28.96 | −$34,375.52 | 74,406 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | Common stock | AGrant or awardAcquired | +14,000 | $0.00 | $0 | 14,000 | Direct | |
| Mar 1, 2026 | Common stock | AGrant or awardAcquired | +22,000 | $0.00 | $0 | 22,000 | Direct | |
| Mar 1, 2026 | Common stock | AGrant or awardAcquired | +52,000 | $0.00 | $0 | 52,000 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 0 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −5,666 | $0.00 | $0 | 5,667 | Direct | |
| Mar 2, 2026 | Common stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 8,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.